Telix Pharmaceuticals (NASDAQ:TLX) Shares Gap Up - Here's Why

Key Points

• Telix Pharmaceuticals shares gapped up significantly, opening at $9.95 after closing at $9.57, and further increased to $10.09 with a trading volume of 15,494 shares.
• Analysts have varied target price forecasts for Telix Pharmaceuticals, with a consensus average target price of $21.00 and five analysts rating it as a "Buy".
• Recent institutional investments included significant new stakes from firms such as Pier Capital LLC, which acquired $3,037,000 in shares, highlighting growing interest in the company.

Telix Pharmaceuticals Limited (NASDAQ:TLX - Get Free Report) shares gapped up before the market opened on Wednesday . The stock had previously closed at $9.57, but opened at $9.95. Telix Pharmaceuticals shares last traded at $10.09, with a volume of 15,494 shares traded.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on TLX shares. Wedbush reiterated an "outperform" rating and set a $22.00 target price on shares of Telix Pharmaceuticals in a report on Thursday, August 28th. HC Wainwright dropped their target price on Telix Pharmaceuticals from $23.00 to $20.00 and set a "buy" rating on the stock in a report on Wednesday, September 10th. Citigroup started coverage on Telix Pharmaceuticals in a research note on Thursday, September 18th. They issued a "buy" rating and a $22.00 price objective on the stock. JPMorgan Chase & Co. restated a "neutral" rating on shares of Telix Pharmaceuticals in a research note on Thursday, August 28th. Finally, UBS Group dropped their price objective on Telix Pharmaceuticals from $23.00 to $20.00 and set a "buy" rating on the stock in a research note on Tuesday, September 23rd. Five investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $21.00.

Telix Pharmaceuticals Stock Performance

The firm has a 50-day moving average price of $11.06 and a 200 day moving average price of $14.76. The company has a debt-to-equity ratio of 0.99, a current ratio of 2.78 and a quick ratio of 2.66.

Institutional Investors Weigh In On Telix Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in TLX. Private Advisor Group LLC acquired a new stake in Telix Pharmaceuticals during the first quarter worth approximately $170,000. ABC Arbitrage SA acquired a new stake in shares of Telix Pharmaceuticals during the 1st quarter valued at $451,000. Blair William & Co. IL acquired a new stake in shares of Telix Pharmaceuticals during the 2nd quarter valued at $217,000. Vanguard Personalized Indexing Management LLC acquired a new stake in shares of Telix Pharmaceuticals during the 2nd quarter valued at $297,000. Finally, Pier Capital LLC acquired a new stake in shares of Telix Pharmaceuticals during the 2nd quarter valued at $3,037,000.

About Telix Pharmaceuticals

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.